Inhibition of human immunodeficiency virus (HIVL/HTLVIIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2,3'-dideoxynucleosides

Journal of Experimental Medicine

Volumn 168, Issue 3, 1988, Pages 1111-1125

  Perno, Carlo Federico ^a   Yarchoan, Robert ^a   Cooney, David A ^a   Hartman, Neil R ^a   Gartner, Suzanne ^b   Popovic, Mikulas ^b   Hao, Zhang ^a   Gerrard, Theresa L ^c   Wilson, Yvonne A ^a   Johns, David G ^a   Broder, Samuel ^a  

^a National Cancer Institute ^*  (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYADENOSINE; ZALCITABINE; ZIDOVUDINE;

HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DEOXYCYTIDINE KINASE; DIDEOXYADENOSINE; DIDEOXYNUCLEOSIDES; HIV; HUMAN; IN VITRO; MACROPHAGES; MONOCYTES; PHOSPHORYLATION; THYMIDINE KINASE; TIME FACTORS; VIRUS REPLICATION; ZALCITABINE; ZIDOVUDINE;

EID: 0023785829     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.168.3.1111     Document Type: Article

References (50)

1. Popovic, M., M. G. Sarngaradharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLVIII) from patients with AIDS and pre-AIDS. Science (Wash. DC). 224: 497.
2. Barre’-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blein, F. BrunVezinet, C. Rozioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation ofa Tlymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science (Wash. DC). 220: 868.
3. Klatzmann, D., E Barre’-Sinoussi, M. T. Nugeyre, C. Dauguet, E. Vilmer, C. Griscelli, F. BrunVezinet, C. Rouzioux, J. C. Gluckman, J. C. Chermann, and L. Montagnier. 1984. Selective tropism of lymphoadenopath-associated virus (LAV) for helper-inducer T lymphocytes. Science (Wash. DC). 225: 59.
4. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLVIII/LAV infection. Science (Wash. DC). 233: 215.
5. Ho, D. D., T. R. Rota, and M. S. Hirsch. 1986. Infection of monocyte/macrophages by human T lymphotropic virus type III.J. Clin. Invest. 77: 1712.
6. Nicholson, J. K. A., G. D. Cross, C. S. Callaway, and J. S. McDougal. 1986. In vitro infection of human monocytes with human T lymphotropic virus type III/lymphoadenopath-associated virus (HTLVIII/LAV). J. Immunol. 137: 323.
7. Tschachler, E., V. Groh, M. Popovic, D. L. Mann, K. Konrad, B. Safai, L. Eton, F. diMarzo Veronese, K. Wolff, and G. Stingl. 1987. Epidermal Langerhans cells: A target for HTLVIII/LAV infection.J. Invest. Dermatol. 88: 233.
8. Crowe, S., J. Mills, and M. S. McGrath. 1987. Quantitative immunocytofluorographic analysis of CD4 surface antigen expression and HIV infection ofhuman peripheral blood monocyte/macrophages. AIDS Res. Hum. Retrooir 3: 135.
9. Chantal Petit, A. J., M. Tersmette, F. G. Terpstra, R. E. Y. de Goede, R. A. W. van Lier, and F. Miedema. 1988. Decreased accessory cell function by human monocytic cells after infection with HIV. J. Immunol. 140: 1485.
10. Gartner, S., P. Markovits, D. M. Markovitz, R. F. Betts, and M. Popovic. 1986. Virus isolation from and identification of HTLVIII/LAVproducing cells in brain tissue from a patient with AIDS. J. Am. Med. Assoc. 256: 2365.
11. Koenig, S., H. E. Gendelman, J. M. Orenstein, M. C. Dal Canto, G. H. Pezeshkpour, M. Yungbluth, F. Janotta, A. Aksamit, M. A. Martin, and A. S. Fauci. 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (Wash. DC. 233: 1089.
12. Gabuzda, D. H., and M. S. Hirsch. 1987. Neurologi c manifestations of infection with human immunodeficiency virus. Ann. Intern. Med. 107: 383.
13. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. Nusinoff Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 1985. 3'-Azido-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect ofhuman Tlymphotropic virus type III/lymphoadenopath-associated virus in vitro. Proc. Natl. Acad. Sci. USA. 82: 7096.
14. Mitsuya, H., and S. Broder. 1986. Inhibition of the in vitro infectivity and cytophatic effect ofhuman Tlymphotropic virus type III/lymphadenopath-associated virus (HTLV III/LAV) by 2',3'-dideoxynucleosides. Proc. Natl. Acad. Sci. USA. 83: 1911.
15. Yarchoan, R., R. W. Klecker, K. J. Weinhold, P D. Markham, H. K. Lyerly, D. T. Durack, E. Gelmann, S. Nusinoff Lehrman, R. M. Blum, D. W. Barry, G. M. Shearer, M. A. Fischl, H. Mitsuya, R. C. Gallo, J. M. Collins, D. P. Bolognesi, C. E. Myers, and S. Broder. 1986. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. i: 575.
16. Yarchoan, R., C. F. Perno, R. V. Thomas, R. W. Klecker, J. P. Allain, R. J. Willis, N. McAtee, M. A. Fischl, R. Dubinsky, M. C. McNeely, H. Mitsuya, J. M. Pluda, T. J. Lawley, M. Leuther, B. Safai, J. M. Collins, C. E. Myers, and S. Broder. 1988. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1: 76.
17. Fischl, M. A., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. King, and the AZT collaborative working group. 1987. The efficacy of azidothymidine (AZT) in the treatment ofpatients with AIDS and AIDS-related complex. A double-blind placebo-controlled trial. N. Engl. J. Med. 317: 185.
18. Furman, P A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. N. Rideout, G. A. Freeman, S. Nusinoff Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-tri phosphate with human immunodeficiency virus reverse transcriptase. Proc. Nad. Acad. Sci. USA. 83: 8333.
19. Cooney, D. A., M. Dalal, H. Mitsuya, J. B. McMahon, M. Nadkarni, J. Balzarini, S. Broder, and D. G. Johns. 1986. Initial studies on the cellular pharmacology of 2', 3'-dideoxycytidine, an inhibitor of HTLVIII infectivity. Biochem. Pharmacol. 35: 2065.
20. Cooney, D. A., G. Ahluwalia, H. Mitsuya, A. Fridland, M. Johnson, Z. Hao, M. Dalal, J. Balzarini, S. Broder, and D. G. Johns. 1987. Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 36: 1765.
21. Waqar, M. A., M. J. Evans, K. F. Manly, R. G. Hughes, and J. A. Huberman. 1984. Effects of2',3'-dideoxynucleosides on mammalian cells and viruses.J. Cell. Physiol. 121: 402.
22. Eriksson, B., L. Vrang, H. Bazin, J. Chattopadhyaya, and B. Oberg. 1987. Different patterns of inhibition of avian myeloblastosis virus reverse transcriptase activity by 3'-azido-3'-deoxythymidine 5'-triphosphate and its threo isomer. Antimicrob. Agents Chemother 31: 600.
23. Vrang, L., H. Bazin, G. Remaud, J. Chattopadhyaya, and B. Oberg. 1987. Inhibition of the reverse transcriptase from HIV by 3'-azido-3'-deoxythymidine triphosphate and its threo analogue. Antiviral Res. 7: 139.
24. Richman, D. D., R. S. Kornbluth, and D. A. Carson. 1987. Failur e of dideoxynucleosides to inhibit HIV replication in cultured human macrophages.] Exp. Med. 166: 1144.
25. Barankiewicz, J., and A. Cohen. 1985. Purine nucleotide metabolism in resident and activated rat macrophages in vitro. Eur. I. Immunol. 15: 627.
26. Zuckerman, S. H., S. K. Ackerman, and S. D. Douglas. 1979. Long-term human peripheral blood monocyte cultures: Establishment, metabolism and morphology of primary human monocyte-macrophage cell cultures. Immunology. 38: 401.
27. Zuckerman, S. H., and S. D. Douglas. 1980. Adenosin e kinase activity during in vitro culture of human peripheral blood monocytes and pulmonary alveolar macrophages. Cell. Immunol. 56: 478.
28. Stadecker, M. J. 1981. Comparison of pyrimidine and purine nucleoside secretion and nucleoside kinase expression in resident and elicited peritoneal macrophages.) Immunol. 126: 1724.
29. Gerrard, T. L., C. H. Jurgensen, and A. S. Fauci. 1983. Differential effect ofmonoclonal anti-DR antibody on monocytes in antigen-and mitogen-stimulated responses: Mechanism of inhibition and relationship to interleukin-1 secretion. Cell. Immunol. 82: 394.
30. Yarchoan, R., B. R. Murphy, W. Strober, H. S. Schneider, and D. L. Nelson. 1981. Specific anti-influenza virus antibody production in vitro by human peripheral blood mononuclear cells. J. Immunol. 127: 2588.
31. Di Marzo Veronese, F., T. D. Copeland, A. L. De Vico, R. Rahman, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan. 1986. Characterization ofhighly immunogenic p66/p51 as the reverse transcriptase of HTLUIII/LAV. Science (Wash. DC). 231: 1289.
32. Mitsuya, H., M. Matsukura, and S. Broder. 1987. Rapid in vitro system for assessing activity of agents against HTLUIII/LAV. In AIDS. Modern concepts and therapeutic challenges. S. Broder, editor. Marcel Dekker, Inc., New York. 303-333.
33. Garrett, C., and D. V. Santi. 1979. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal. Biochem. 99: 268.
34. Ahluwalia, G. S., M. B. Cohen, G. J. Kang, S. T. Arnold, J. B. McMahon, M. Dalal, Y. A. Wilson, D. A.Cooney, J. Balzarini, and D. G. Johns. 1986. Arabinosyl-β-azacytosine: Mechanism of native and acquired resistance. Cancer Res. 46: 4479.
35. Pereira, L., M. Hoffman, and N. Cremer. 1982. Electrophoretic analysis ofpolypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera. Infect. Immun. 36: 933.
36. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phipps, L. A. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, D. Skillman, and M. S. Meltzer. 1988. Efficien t isolation and propagation of human immunodeficiency virus on recombinant colon-stimulating factor 1-treated monocytes. J. Exp. Med. 167: 1428.
37. Smith, M. S., E. L. Brian, andJ. S. Pagano. 1987. Resumption of virus production after human immunodeficiency virus infection of Tlymphocytes in the presence of azidothymidine. J. Virol. 61: 3769.
38. Mitsuya H., and S. Broder. 1988. Progress in the therapy of human immunodeficiency virus (HIV) infections. In Retrovirus biology: An emerging role in human diseases. R. C. Gallo and F. Wong-Staal, editors. In press.
39. Ho, D. D., R. J. Pomerantz, and J. C. Kaplan. 1987. Pathogenesi s of infection with human immunodeficiency virus. N. Engl. J. Med. 317: 278.
40. Sodroski, J., W. C. Goh, C. Rosen, K. Campbell, and W. A. Haseltine. 1986. Role of the HTLVIII/LAV envelope in syncytium formation and cytopathicity. Nature (Lond.). 322: 470.
41. Lifson, J. D., M. B. Feinberg, G. R. Reyes, L. Rabin, B. Banapour, S. Chakrabarti, B. Moss, F. Wong-Staal, K. S. Steimer, and E. G. Engleman. 1986. Induction of CD4-dependent cell fusion by the HTLVIII/LAV envelope glycoprotein. Nature (Load.). 323: 725.
42. Chan, T. S. 1979. Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity. Proc. Natl. Acad. Sci. USA. 76: 925.
43. Chan, T. S., and B. D. Lakhchaura. 1982. Deoxycytidin e excretion by mouse peritoneal macrophages: Its implication in modulation of immunological functions. J Cell. Physiol. 111: 28.
44. Stadecker, M. J., J. Calderon, M. L. Karnovsky, and E. R. Unanue. 1977. Synthesi s and release of thymidine by macrophages. J. Immunol. 119: 1738.
45. Mitsuya, H., R. F. Jarrett, M. Matsukura, F. Di Marzo Veronese, A. L. DeVico, M. G. Sarngadharan, D. G. Johns, M. S. Reitz, and S. Broder. 1987. Long term inhibition ofhumanTlymphotropic virus type III/lymphoadenopath-associated virus (human im munodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc. Natl. Acad. Sci. USA. 84: 2033.
46. Dahlberg, J. E., H. Mitsuya, S. B. Blam, S. Broder, and S. A. Aaronson. 1987. Broadspectrum antiretroviral activity of 2,3'-dideoxynucleosides. Proc. Natl. Acad. Sci. USA. 84: 2469.
47. Mitsuya, H., J. E. Dahlberg, Z. Spiegelman, S. Matsushita, R. F. Jarrett, M. Matsukura, M. J. Currens, S. A. Aaronson, M. S. Reitz, R. S. McCaffrey, and S. Broder. 1988. 2',3'-dideoxynucleosides: broad spectrum antiviral activity and mechanism of action. In Human Retrovirus, Cancer, and AIDS: Approaches to prevention and therapy. D. P Bolognesi, editor. Alan R. Liss, Inc., New York. 407-421.
48. Balzarini, J., D. A. Cooney, M. Dalal, G. J. Kang, J. E. Cupp, E. De Clercq, S. Broder, and D. G. Johns. 1987. 2',3'-Dideoxycytidine: Regulation of its metabolism and antiretroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32: 798.
49. Yarchoan, R., G. Berg, P Browers, M. A. Fischl, A. R. Spitzer, A. Wichman, J. Grafman, R. V. Thomas, B. Safai, A. Brunetti, C. F. Perno, P J. Schmidt, S. M. Larson, C. E. Myers, and S. Broder. 1987. Response ofhuman immunodeficiency virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1: 132.
50. Yarchoan, R., R. V. Thomas, J. Grafman, A. Wichman, M. Dalakas, N. McAtee, G. Berg, M. Fischl, C. F. Perno, R. W. Klecker, A. Buchbinder, S. Tay, S. M. Larson, C. E. Myers, and S. Brader. 1988. Long-term administration of3'-azido-2,3'-dideoxythymidine to patients with AIDS-related neurological disease. Ann. Neurol. 23: S82.